GLP-1 receptor agonists and vascular protection
Am J Physiol Heart Circ Physiol. 2024 Mar 1. doi: 10.1152/ajpheart.00574.2023. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease is a chronic condition that often co-presents with type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetics endorsed by major professional societies for improving glycemic status and reducing atherosclerotic risk in people living with type 2 diabetes. While the cardioprotective efficacy of GLP-1RAs and their relationship with traditional risk factors are well-established, there is a paucity of publications that have summarized the ...
Source: Atherosclerosis - March 1, 2024 Category: Cardiology Authors: Brady Park Ehab Bakbak Hwee Teoh Aishwarya Krishnaraj Fallon Dennis Adrian Quan Ori D Rotstein Javed Butler David A Hess Subodh Verma Source Type: research
Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia
Curr Diabetes Rev. 2024 Feb 29. doi: 10.2174/0115733998279875240216093902. Online ahead of print.ABSTRACTDementia is the primary cause of disability and dependence among the elderly population worldwide. The population living with dementia is anticipated to double in the next 17 years. Recent studies show the fact that compared to people without diabetes, people with Type 2 Diabetes (T2D) have about a 60% increased chance of developing dementia. In addition to cholinergic function being downregulated, improper insulin signalling also has a negative impact on synaptic plasticity and neuronal survival. Type 2 diabetes and de...
Source: Current Diabetes Reviews - March 1, 2024 Category: Endocrinology Authors: Deepika Joshi Source Type: research
GLP-1 receptor agonists and vascular protection
Am J Physiol Heart Circ Physiol. 2024 Mar 1. doi: 10.1152/ajpheart.00574.2023. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease is a chronic condition that often co-presents with type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetics endorsed by major professional societies for improving glycemic status and reducing atherosclerotic risk in people living with type 2 diabetes. While the cardioprotective efficacy of GLP-1RAs and their relationship with traditional risk factors are well-established, there is a paucity of publications that have summarized the ...
Source: American Journal of Physiology. Heart and Circulatory Physiology - March 1, 2024 Category: Physiology Authors: Brady Park Ehab Bakbak Hwee Teoh Aishwarya Krishnaraj Fallon Dennis Adrian Quan Ori D Rotstein Javed Butler David A Hess Subodh Verma Source Type: research
GLP-1 receptor agonists and vascular protection
Am J Physiol Heart Circ Physiol. 2024 Mar 1. doi: 10.1152/ajpheart.00574.2023. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease is a chronic condition that often co-presents with type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetics endorsed by major professional societies for improving glycemic status and reducing atherosclerotic risk in people living with type 2 diabetes. While the cardioprotective efficacy of GLP-1RAs and their relationship with traditional risk factors are well-established, there is a paucity of publications that have summarized the ...
Source: Atherosclerosis - March 1, 2024 Category: Cardiology Authors: Brady Park Ehab Bakbak Hwee Teoh Aishwarya Krishnaraj Fallon Dennis Adrian Quan Ori D Rotstein Javed Butler David A Hess Subodh Verma Source Type: research
Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia
Curr Diabetes Rev. 2024 Feb 29. doi: 10.2174/0115733998279875240216093902. Online ahead of print.ABSTRACTDementia is the primary cause of disability and dependence among the elderly population worldwide. The population living with dementia is anticipated to double in the next 17 years. Recent studies show the fact that compared to people without diabetes, people with Type 2 Diabetes (T2D) have about a 60% increased chance of developing dementia. In addition to cholinergic function being downregulated, improper insulin signalling also has a negative impact on synaptic plasticity and neuronal survival. Type 2 diabetes and de...
Source: Current Diabetes Reviews - March 1, 2024 Category: Endocrinology Authors: Deepika Joshi Source Type: research
GLP-1 receptor agonists and vascular protection
Am J Physiol Heart Circ Physiol. 2024 Mar 1. doi: 10.1152/ajpheart.00574.2023. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease is a chronic condition that often co-presents with type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetics endorsed by major professional societies for improving glycemic status and reducing atherosclerotic risk in people living with type 2 diabetes. While the cardioprotective efficacy of GLP-1RAs and their relationship with traditional risk factors are well-established, there is a paucity of publications that have summarized the ...
Source: American Journal of Physiology. Heart and Circulatory Physiology - March 1, 2024 Category: Physiology Authors: Brady Park Ehab Bakbak Hwee Teoh Aishwarya Krishnaraj Fallon Dennis Adrian Quan Ori D Rotstein Javed Butler David A Hess Subodh Verma Source Type: research
Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia
Curr Diabetes Rev. 2024 Feb 29. doi: 10.2174/0115733998279875240216093902. Online ahead of print.ABSTRACTDementia is the primary cause of disability and dependence among the elderly population worldwide. The population living with dementia is anticipated to double in the next 17 years. Recent studies show the fact that compared to people without diabetes, people with Type 2 Diabetes (T2D) have about a 60% increased chance of developing dementia. In addition to cholinergic function being downregulated, improper insulin signalling also has a negative impact on synaptic plasticity and neuronal survival. Type 2 diabetes and de...
Source: Current Diabetes Reviews - March 1, 2024 Category: Endocrinology Authors: Deepika Joshi Source Type: research
GLP-1 receptor agonists and vascular protection
Am J Physiol Heart Circ Physiol. 2024 Mar 1. doi: 10.1152/ajpheart.00574.2023. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease is a chronic condition that often co-presents with type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetics endorsed by major professional societies for improving glycemic status and reducing atherosclerotic risk in people living with type 2 diabetes. While the cardioprotective efficacy of GLP-1RAs and their relationship with traditional risk factors are well-established, there is a paucity of publications that have summarized the ...
Source: American Journal of Physiology. Heart and Circulatory Physiology - March 1, 2024 Category: Physiology Authors: Brady Park Ehab Bakbak Hwee Teoh Aishwarya Krishnaraj Fallon Dennis Adrian Quan Ori D Rotstein Javed Butler David A Hess Subodh Verma Source Type: research
Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia
Curr Diabetes Rev. 2024 Feb 29. doi: 10.2174/0115733998279875240216093902. Online ahead of print.ABSTRACTDementia is the primary cause of disability and dependence among the elderly population worldwide. The population living with dementia is anticipated to double in the next 17 years. Recent studies show the fact that compared to people without diabetes, people with Type 2 Diabetes (T2D) have about a 60% increased chance of developing dementia. In addition to cholinergic function being downregulated, improper insulin signalling also has a negative impact on synaptic plasticity and neuronal survival. Type 2 diabetes and de...
Source: Current Diabetes Reviews - March 1, 2024 Category: Endocrinology Authors: Deepika Joshi Source Type: research
GLP-1 receptor agonists and vascular protection
Am J Physiol Heart Circ Physiol. 2024 Mar 1. doi: 10.1152/ajpheart.00574.2023. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease is a chronic condition that often co-presents with type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetics endorsed by major professional societies for improving glycemic status and reducing atherosclerotic risk in people living with type 2 diabetes. While the cardioprotective efficacy of GLP-1RAs and their relationship with traditional risk factors are well-established, there is a paucity of publications that have summarized the ...
Source: American Journal of Physiology. Heart and Circulatory Physiology - March 1, 2024 Category: Physiology Authors: Brady Park Ehab Bakbak Hwee Teoh Aishwarya Krishnaraj Fallon Dennis Adrian Quan Ori D Rotstein Javed Butler David A Hess Subodh Verma Source Type: research
Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia
Curr Diabetes Rev. 2024 Feb 29. doi: 10.2174/0115733998279875240216093902. Online ahead of print.ABSTRACTDementia is the primary cause of disability and dependence among the elderly population worldwide. The population living with dementia is anticipated to double in the next 17 years. Recent studies show the fact that compared to people without diabetes, people with Type 2 Diabetes (T2D) have about a 60% increased chance of developing dementia. In addition to cholinergic function being downregulated, improper insulin signalling also has a negative impact on synaptic plasticity and neuronal survival. Type 2 diabetes and de...
Source: Current Diabetes Reviews - March 1, 2024 Category: Endocrinology Authors: Deepika Joshi Source Type: research
GLP-1 receptor agonists and vascular protection
Am J Physiol Heart Circ Physiol. 2024 Mar 1. doi: 10.1152/ajpheart.00574.2023. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease is a chronic condition that often co-presents with type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetics endorsed by major professional societies for improving glycemic status and reducing atherosclerotic risk in people living with type 2 diabetes. While the cardioprotective efficacy of GLP-1RAs and their relationship with traditional risk factors are well-established, there is a paucity of publications that have summarized the ...
Source: American Journal of Physiology. Heart and Circulatory Physiology - March 1, 2024 Category: Physiology Authors: Brady Park Ehab Bakbak Hwee Teoh Aishwarya Krishnaraj Fallon Dennis Adrian Quan Ori D Rotstein Javed Butler David A Hess Subodh Verma Source Type: research
Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia
Curr Diabetes Rev. 2024 Feb 29. doi: 10.2174/0115733998279875240216093902. Online ahead of print.ABSTRACTDementia is the primary cause of disability and dependence among the elderly population worldwide. The population living with dementia is anticipated to double in the next 17 years. Recent studies show the fact that compared to people without diabetes, people with Type 2 Diabetes (T2D) have about a 60% increased chance of developing dementia. In addition to cholinergic function being downregulated, improper insulin signalling also has a negative impact on synaptic plasticity and neuronal survival. Type 2 diabetes and de...
Source: Current Diabetes Reviews - March 1, 2024 Category: Endocrinology Authors: Deepika Joshi Source Type: research
Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia
Curr Diabetes Rev. 2024 Feb 29. doi: 10.2174/0115733998279875240216093902. Online ahead of print.ABSTRACTDementia is the primary cause of disability and dependence among the elderly population worldwide. The population living with dementia is anticipated to double in the next 17 years. Recent studies show the fact that compared to people without diabetes, people with Type 2 Diabetes (T2D) have about a 60% increased chance of developing dementia. In addition to cholinergic function being downregulated, improper insulin signalling also has a negative impact on synaptic plasticity and neuronal survival. Type 2 diabetes and de...
Source: Current Diabetes Reviews - March 1, 2024 Category: Endocrinology Authors: Deepika Joshi Source Type: research
Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia
Curr Diabetes Rev. 2024 Feb 29. doi: 10.2174/0115733998279875240216093902. Online ahead of print.ABSTRACTDementia is the primary cause of disability and dependence among the elderly population worldwide. The population living with dementia is anticipated to double in the next 17 years. Recent studies show the fact that compared to people without diabetes, people with Type 2 Diabetes (T2D) have about a 60% increased chance of developing dementia. In addition to cholinergic function being downregulated, improper insulin signalling also has a negative impact on synaptic plasticity and neuronal survival. Type 2 diabetes and de...
Source: Current Diabetes Reviews - March 1, 2024 Category: Endocrinology Authors: Deepika Joshi Source Type: research
